©News Group Newspapers Limited in England No. 679215 Registered office: 1 London Bridge Street, London, SE1 9GF. "The Sun", ...

A dreaded fungus known to inhabit tombs has been reconstituted as a treatment for leukemia and is performing as effectively ...

Vermont has the second lowest state fatality rate in the US (147.9 per 100K; Hawaii 113.5/100K). Mississippi (465.6/100K) and ...

Medtech Products is recalling five lots of its Little Remedies Honey Cough Syrup for bacterial contamination. The food-borne illness causes gastrointestinal symptoms, which can be mild in healthy ...

Norovirus GII.17 accounted for < 10% of outbreaks in the US 2022-23 season, but rose to 75% during the 2024-25 season, passing the number of GII.4 outbreaks.

Vaxart, Inc., a biotechnology company focused on oral recombinant pill vaccines, announced it will release topline data from its Phase I trial on norovirus before the market opens on June 11, 2025.

In previous years, the U.S. saw norovirus outbreaks increase around December, which marked the start of the season of the virus. Between 2011 and 2024, GII.4 viruses caused less than 50% of US ...

Dr. Mallika Marshall has more on both stories in this edition of Healthwatch. Musk jokes about reconsidering stance on Big Beautiful Bill after Schiff's praise John Wick Boss Slams Spin-Off Series ...

There are 900 deaths on average each year and between 19 and 21 million illnesses. There’s no specific treatment for norovirus, but most people recover with a period of up to three days.

“Cocrystal developed CDI-988 as a potential breakthrough for norovirus prophylaxis and treatment using our proprietary structure-based platform technology. Unlike conventional antivirals, it ...

BOTHELL, Wash., June 05, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that its broad-spectrum protease inhibitor CDI-988 will be featured in an oral presentation at the ...